Testing lower doses of radiation for metastatic tumors with ATM mutations

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate the effectiveness of reduced-dose radiotherapy in treating metastatic tumors that have a pathogenic mutation in the ATM gene. Researchers will determine the minimum effective radiation dose that can still provide therapeutic benefits for patients with these specific tumors. The study focuses on patients who are referred for palliative radiotherapy and have a confirmed malignancy with at least one metastatic lesion. The goal is to improve treatment outcomes while minimizing radiation exposure.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically confirmed malignancy with at least one metastatic lesion referred for palliative radiotherapy
* Pathogenic mutation in ATM (somatic and germline allowed)
* ECOG performance status 0-2
* Age ≥ 18 years.
* Able to provide informed consent.
* Patients at reproductive potential must agree to practice an effective contraceptive method during radiation treatments.
* Expected life expectancy of at least 6 months

Exclusion Criteria:

* Previous radiotherapy to the intended treatment site that precludes developing a treatment plan that respects normal tissue tolerances.
* Serious medical co-morbidities precluding radiotherapy.
* Pregnant or breast-feeding women.
* Lesions excluded from de-escalation include regions in which the risk of local disease progression is unacceptably high, including CNS disease and cord compression, and areas in which re-irradiation would not be feasible, including spinal cord overlap.

Where it's running

• Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
  Basking Ridge, New Jersey, United States Recruiting
• Memorial Sloan Kettering Monmouth (All protocol activities)
  Middletown, New Jersey, United States Recruiting
• Memorial Sloan Kettering Bergen (All protocol activities)
  Montvale, New Jersey, United States Recruiting
• Memorial Sloan Kettering Commack (All protocol activities)
  Commack, New York, United States Recruiting
• Memorial Sloan Kettering Westchester (All Protocol Activities)
  Harrison, New York, United States Recruiting
• Memorial Sloan Kettering Cancer Center (All Protocol Activities)
  New York, New York, United States Recruiting

Study contacts

• Principal investigator: Amy Xu, MD, PhD — Memorial Sloan Kettering Cancer Center
• Study coordinator: Amy Xu, MD, PhD
• Email: xua@mskcc.org
• Phone: 646-888-6863

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• IL-15–Enhanced NK Cell Therapy for Solid Tumors

  A first-in-human, early-phase study tests whether IL-15–enhanced engineered NK cells are safe and can show early signs of effect in adults with relapsed or metastatic solid tumors.

  Recruiting Early Phase 1 Genovn Therapeutics PTE. LTD. · Chongqing · NCT07621471

• LATTICE radiotherapy vs moderately dose-escalated palliative radiation for metastases

  This study tests whether LATTICE radiotherapy given in 5 fractions works better than a standard palliative dose for patients with metastatic cancer who have 1–2 sizable tumors.

  Recruiting Phase 2 Stanford University · Palo Alto, California · NCT07594431

• Givastomig with nivolumab and chemotherapy for CLDN18.2-positive metastatic stomach or gastroesophageal junction cancer

  This study will see if adding givastomig to nivolumab plus standard chemotherapy helps adults with CLDN18.2- and PD-L1-positive metastatic stomach or gastroesophageal junction cancer live longer without their disease getting worse.

  Recruiting at 5 sites Phase 2 I-Mab Biopharma US Limited · Goodyear, Arizona and 5 other locations · NCT07432295

• Support program for parents living with advanced cancer

  This study tests whether adding experiential sessions to a psycho-educational program helps parents with advanced cancer communicate better with their children aged 10–25.

  Recruiting Université Libre de Bruxelles · Anderlecht · NCT07341815

• POLARIS — Ablative radiotherapy with immunotherapy for people with multiple metastatic lesions

  This pilot tests whether giving focused high-dose radiation to up to 10 metastatic tumors while patients are on immunotherapy helps people with advanced solid tumors who have 3–10 metastases.

  Recruiting Phase 1 University of Illinois Chicago · Chicago, Illinois · NCT07269080

• Adding Y‑NM600 imaging and targeted Y‑90 radiation to anti‑PD‑1/PD‑L1 treatment for metastatic cancer

  This will test whether giving radioactive Y‑NM600 imaging and a targeted Y‑90 radiation dose to people with metastatic cancer who are on anti‑PD‑1 or anti‑PD‑L1 medicines is safe and can help those medicines work better.

  Recruiting Phase 1 University of Wisconsin, Madison · Madison, Wisconsin · NCT07197671

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.